Bicara Therapeutics (BCAX) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$17.50
+1.4% on the day
-4.2% over 12 months
52-week range $13.93 – $30.40
Share price and insider trades
BCAX closeInsider buyInsider sale
Bought, 12 months$4.8M
Sold, 12 months$11.6M
Insiders buying1
Insiders selling4
Bicara Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $4.8M and 4 sold $11.6M of BCAX stock on the open market.
Get emailed when insiders cluster-buy stocks like BCAX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
BCAX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $3.5M | 14 |
| Q2 2026 | — | 0 | $1.7M | 10 |
| Q1 2026 | $4.8M | 1 | $2.8M | 22 |
| Q4 2025 | — | 0 | $5.1M | 25 |
| Q3 2025 | — | 0 | $499K | 1 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.4×Last 5 sessions
Insiders' paper profit+$450KOn all tracked purchases +9.4%
Summary
Over the past 12 months, 1 Bicara Therapeutics Inc. insider reported open-market purchases totaling $4.8M, while 4 insiders reported sales totaling $11.6M. Among insiders with enough purchase history to measure, Ra Capital Management, L.P. (Director) has the highest Insider Score at 92. 72 of 72 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 10SEC | Ryan CohlheppCEO, COO | Sell Plan | 14,058185,083 held (−7%) | $22.77 | $320K | -23.1% | — |
| Sep 10SEC | Ryan CohlheppCEO, COO | Sell Plan | 3,442181,641 held (−2%) | $23.43 | $81K | -25.3% | — |
| Aug 12SEC | Ryan CohlheppCOO, President | Sell Plan | 18,750181,641 held (−9%) | $27.98 | $525K | -37.5% | — |
| Aug 12SEC | Ivan HyepCFO | Sell Plan | 12,500129,855 held (−9%) | $27.97 | $350K | -37.4% | — |
| Aug 12SEC | Claire MazumdarCEO | Sell Plan | 10,000362,152 held (−3%) | $27.98 | $280K | -37.5% | — |
| Jul 14SEC | Claire MazumdarCEO | Sell Plan | 9,972362,180 held (−3%) | $28.42 | $283K | -38.4% | — |
| Jul 14SEC | Claire MazumdarCEO | Sell Plan | 28362,152 held (−0%) | $29.68 | $831 | -41.0% | — |
| Jul 10SEC | Ryan CohlheppCOO, President | Sell Plan | 22,833187,558 held (−11%) | $28.76 | $657K | -39.2% | — |
| Jul 10SEC | Ivan HyepCFO | Sell Plan | 22,757135,098 held (−14%) | $28.60 | $651K | -38.8% | — |
| Jul 10SEC | Ivan HyepCFO | Sell Plan | 4,413130,685 held (−3%) | $29.82 | $132K | -41.3% | — |
| Jul 10SEC | Ryan CohlheppCOO, President | Sell Plan | 4,306183,252 held (−2%) | $29.80 | $128K | -41.3% | — |
| Jul 10SEC | Ryan CohlheppCOO, President | Sell Plan | 1,075182,177 held (−1%) | $30.35 | $33K | -42.3% | — |
| Jul 10SEC | Ivan HyepCFO | Sell Plan | 830129,855 held (−1%) | $30.31 | $25K | -42.3% | — |
| Jul 10SEC | Ryan CohlheppCOO, President | Sell Plan | 536181,641 held (−0%) | $29.00 | $16K | -39.7% | — |
| May 26SEC | Ivan HyepCFO | Sell Plan | 9,200145,355 held (−6%) | $20.42 | $188K | -14.3% | — |
| May 20SEC | Claire MazumdarCEO | Sell Plan | 12,022365,130 held (−3%) | $19.96 | $240K | -12.3% | — |
| May 20SEC | Claire MazumdarCEO | Sell Plan | 2,978362,152 held (−1%) | $20.35 | $61K | -14.0% | — |
| May 18SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000196,141 held (−4%) | $20.29 | $162K | -13.8% | — |
| May 18SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500191,641 held (−2%) | $20.29 | $91K | -13.8% | — |
| Apr 28SEC | David RabenChief Medical Officer | Sell Plan | 5,50055,286 held (−9%) | $22.88 | $126K | -23.5% | — |
| Apr 22SEC | Ivan HyepCFO | Sell Plan | 9,200145,355 held (−6%) | $23.00 | $212K | -23.9% | — |
| Apr 20SEC | Claire MazumdarCEO | Sell Plan | 15,000362,152 held (−4%) | $23.61 | $354K | -25.9% | — |
| Apr 17SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000200,641 held (−4%) | $23.01 | $184K | -23.9% | — |
| Apr 17SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500196,141 held (−2%) | $23.01 | $104K | -23.9% | — |
| Mar 26SEC | David RabenChief Medical Officer | Sell Plan | 5,50055,286 held (−9%) | $18.95 | $104K | -7.7% | — |
| Mar 24SEC | Ivan HyepCFO | Sell Plan | 9,200145,355 held (−6%) | $18.52 | $170K | -5.5% | — |
| Mar 20SEC | Claire MazumdarCEO | Sell Plan | 6,905339,392 held (−2%) | $18.78 | $130K | -6.8% | — |
| Mar 20SEC | Claire MazumdarCEO | Sell Plan | 6,499339,392 held (−2%) | $18.84 | $122K | -7.1% | — |
| Mar 20SEC | Claire MazumdarCEO | Sell Plan | 1,596339,392 held (−0%) | $18.95 | $30K | -7.7% | — |
| Mar 17SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000205,141 held (−4%) | $19.66 | $157K | -11.0% | — |
| Mar 17SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500200,641 held (−2%) | $19.66 | $88K | -11.0% | — |
| Mar 11SEC | Claire MazumdarCEO | Sell Plan | 36,766339,392 held (−10%) | $19.17 | $705K | -8.7% | — |
| Mar 6SEC | Claire MazumdarCEO | Sell Plan | 3,817339,392 held (−1%) | $18.75 | $72K | -6.7% | — |
| Mar 6SEC | Claire MazumdarCEO | Sell Plan | 2,631339,392 held (−1%) | $18.73 | $49K | -6.6% | — |
| Mar 6SEC | Claire MazumdarCEO | Sell Plan | 1,786339,392 held (−1%) | $18.74 | $33K | -6.6% | — |
| Mar 5SEC | David RabenChief Medical Officer | Sell Plan | 16,30055,286 held (−23%) | $18.52 | $302K | -5.5% | — |
| Mar 5SEC | Ivan HyepCFO | Sell Plan | 13,555145,355 held (−9%) | $18.22 | $247K | -4.0% | — |
| Mar 5SEC | Ryan CohlheppCOO, President | Sell Plan | 12,892209,641 held (−6%) | $18.16 | $234K | -3.6% | — |
| Mar 5SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500205,141 held (−2%) | $18.16 | $82K | -3.6% | — |
| Mar 5SEC | Ivan HyepCFO | Sell Plan | 2,963145,355 held (−2%) | $18.25 | $54K | -4.1% | — |
| Mar 5SEC | David RabenChief Medical Officer | Sell Plan | 20055,286 held (−0%) | $18.45 | $4K | -5.1% | — |
| Mar 2SEC | Ra Capital Management, L.P.Director | Buy | 300,0004,603,418 held (+7%) | $16.00 | $4.8M | +9.4% | 92 |
| Feb 27SEC | Ryan CohlheppCOO, President | Sell Plan | 3,108210,164 held (−1%) | $18.04 | $56K | -3.0% | — |
| Feb 27SEC | Ryan CohlheppCOO, President | Sell Plan | 523209,641 held (−0%) | $18.04 | $9K | -3.0% | — |
| Jan 26SEC | Ryan CohlheppCOO, President | Sell Plan | 3,828210,164 held (−2%) | $18.10 | $69K | -3.3% | — |
| Jan 26SEC | Ivan HyepCFO | Sell Plan | 1,882145,355 held (−1%) | $18.15 | $34K | -3.6% | — |
| Jan 20SEC | Ryan CohlheppCOO, President | Sell Plan | 149213,992 held (−0%) | $18.02 | $3K | -2.9% | — |
| Dec 23SEC | Ivan HyepCFO | Sell Plan | 9,200145,355 held (−6%) | $18.31 | $168K | -4.4% | — |
| Dec 16SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000193,641 held (−4%) | $18.68 | $149K | -6.3% | — |
| Dec 16SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500189,141 held (−2%) | $18.68 | $84K | -6.3% | — |
| Nov 25SEC | Claire MazumdarCEO | Sell Plan | 41,163309,892 held (−12%) | $18.86 | $776K | -7.2% | — |
| Nov 25SEC | Ivan HyepCFO | Sell Plan | 17,795145,355 held (−11%) | $18.55 | $330K | -5.7% | — |
| Nov 25SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000198,141 held (−4%) | $18.05 | $144K | -3.0% | — |
| Nov 25SEC | David RabenChief Medical Officer | Sell Plan | 5,50035,497 held (−13%) | $18.45 | $101K | -5.1% | — |
| Nov 25SEC | David RabenChief Medical Officer | Sell Plan | 4,59435,497 held (−11%) | $18.84 | $87K | -7.1% | — |
| Nov 25SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500193,641 held (−2%) | $18.05 | $81K | -3.0% | — |
| Nov 25SEC | David RabenChief Medical Officer | Sell Plan | 90635,497 held (−2%) | $18.84 | $17K | -7.1% | — |
| Nov 25SEC | Ivan HyepCFO | Sell Plan | 605145,355 held (−0%) | $18.15 | $11K | -3.6% | — |
| Oct 20SEC | Claire MazumdarCEO | Sell Plan | 24,103309,892 held (−7%) | $18.83 | $454K | -7.1% | — |
| Oct 16SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000202,641 held (−4%) | $18.16 | $145K | -3.6% | — |
| Oct 16SEC | Ryan CohlheppCOO, President | Sell Plan | 4,500198,141 held (−2%) | $18.16 | $82K | -3.6% | — |
| Oct 15SEC | Claire MazumdarCEO | Sell Plan | 13,289309,892 held (−4%) | $18.84 | $250K | -7.1% | — |
| Oct 15SEC | Claire MazumdarCEO | Sell Plan | 11,445309,892 held (−4%) | $18.92 | $217K | -7.5% | — |
| Oct 10SEC | David RabenChief Medical Officer | Sell Plan | 22,00035,497 held (−38%) | $18.45 | $406K | -5.1% | — |
| Oct 10SEC | Ivan HyepCFO | Sell Plan | 6,415145,355 held (−4%) | $18.23 | $117K | -4.0% | — |
| Oct 8SEC | Ryan CohlheppCOO, President | Sell Plan | 24,000221,141 held (−10%) | $18.06 | $433K | -3.1% | — |
| Oct 8SEC | Ivan HyepCFO | Sell Plan | 18,244145,355 held (−11%) | $18.22 | $332K | -4.0% | — |
| Oct 8SEC | Ryan CohlheppCOO, President | Sell Plan | 15,600205,541 held (−7%) | $18.06 | $282K | -3.1% | — |
| Oct 8SEC | Ryan CohlheppCOO, President | Sell Plan | 8,000205,541 held (−4%) | $18.06 | $144K | -3.1% | — |
| Oct 8SEC | Ivan HyepCFO | Sell Plan | 6,514145,355 held (−4%) | $18.17 | $118K | -3.7% | — |
| Oct 8SEC | Ivan HyepCFO | Sell Plan | 5,627145,355 held (−4%) | $18.21 | $102K | -3.9% | — |
| Oct 8SEC | Ryan CohlheppCOO, President | Sell Plan | 2,900202,641 held (−1%) | $18.06 | $52K | -3.1% | — |
| Oct 1SEC | Lara MeisnerGeneral Counsel | Sell Plan | 33,807 | $14.75 | $499K | +18.6% | — |
Insiders at Bicara Therapeutics Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Ra Capital Management, L.P.Director | $4.8M | — | Mar 2, 2026 | 92 |
| Ryan CohlheppCEO, COO | — | $4.6M | Sep 10, 2026 | — |
| Claire MazumdarCEO | — | $4.1M | Aug 12, 2026 | — |
| Ivan HyepCFO | — | $3.2M | Aug 12, 2026 | — |
| David RabenChief Medical Officer | — | $1.1M | Apr 28, 2026 | — |
| Lara MeisnerGeneral Counsel | — | $499K | Oct 1, 2025 | — |
BCAX stock: common questions
Are Bicara Therapeutics Inc. insiders buying BCAX stock?
In the past 12 months, 1 insiders reported open-market purchases of BCAX worth $4.8M. The latest was Director Ra Capital Management, L.P. bought $4.8M of BCAX at $16.00 — first open-market purchase in our records.
Are Bicara Therapeutics Inc. insiders selling BCAX stock?
4 insiders reported sales worth $11.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BCAX's 52-week range?
Over the past year BCAX has traded between $13.93 and $30.40. It last closed at $17.50 on Oct 9, 2026.